In a single-dose pharmacokinetic–pharmacodynamic (PK–PD) study, mice bearing AGK::BRAF fusion melanoma PDX tumors were orally administered tovorafenib at 17.5 or 25 mg/kg. Here, BRAF is linked to melanoma.